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 DEFINITION IN TERMS: 
 
Chi-square test:  Statistical test used to test the null hypothesis that proportions are equal or that 
factors or characteristics are independent or not associated (Dawson & Trapp, 1994). 
Confidence Interval: Gives a range of parameter values considered plausible for the population, 
based on the sample data, and is a useful way of describing the precision of the estimate 
(Katzenellenbogen, Joubert & Abdookarim, 1997). 
Confounding variable: A variable more likely to be present in one group of subjects than 
another that is related to the outcome of interest and thus potentially confuses or confounds the 
results (Dawson & Trapp, 1994). 
Cluster of differentiation antigen 4 (CD4): Is the T lymphocyte antigen receptor component 
and human immunodeficiency virus co receptor, is down-modulated when cells are activated by 
antigen (Pitcher, Honing, Fingerhut, Bowers & Marsh, 1999). 
Independent Variable: The explanatory or predictor variable in a study (Dawson & Trapp, 
1994). 
Negative Predictive Value (NPV): The probability of a person not having a disease when the 
result of a test is negative (Beaglehole, Bonita, & Kjellstrom, 2006). 
Mathematically expressed as: 

Population:    Members of a defined group you want to gather information and make 
conclusions about (Dawson & Trapp, 1994) 
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Prevalence: The number of existing cases (both new and old) of a disease in a given population 
in a geographical area at a specified point or period of time (Beaglehole, Bonita & Kjellstrom, 
2006).  
Mathematically, Prevalence rate is expressed as: 
 
Positive Predictive Value (PPV):  Is the probability of a disease in a patient with abnormal test 
result or person with a positive test has the disease (Beaglehole, Bonita & Kjellstrom, 2006). 
Mathematically expressed as: 
 
P-value: Is the probability of finding an association or a difference, if there is in reality no 
association or no difference (Katzenellenbogen, Joubert & Abdookarim, 1997) 
Reliability:   The observer (or someone else doing the test) repeating the test using same method 
should be able to obtain the same findings (WHO, 2001). 
Relative Risk (R.R): The ratio of the incidence of a given disease in exposed or at risk persons 
to the incidence of the disease in unexposed persons (Dawson & Trapp, 1994). R.R greater than 
1(one) shows an association between the risk (CD4 count ≤200cells/mm3) and the disease (ND). 
R.R=1 no association and R.R less than 1 shows the risk factor is protective.  
Relative Risk is expressed as: 
 
Sample:   Sub-set of the entire population (Katzenellenbogen, Joubert & Karim, 1997) 
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Statistics:   A summary number for a sample, often used as an estimate of a parameter in the 
population (Dawson & Trapp, 1994) 
Standard Deviation (SD): The most common measure of dispersion or spread, it can be used 
with the mean to describe the distribution or spread. It is the square root of the average of the 
squared deviations of the observations from their mean (Dawson & Trapp, 1994) 
Sensitivity: The probability of a positive test result in patients who have the condition (positivity 
in disease) (Dawson & Trapp, 1994). 
Mathematically expressed as: 
 
Specificity:   The probability of a negative test results in patients who do not have the condition 
or the proportion of patients without the condition who test negative (Dawson & Trapp, 1994). 
Mathematically expressed as: 
 
Variables:   Is the characteristics which one measures, and about which data are collected, it can 
be Categorical or Numerical (Katzenellenbogen, Joubert & Abdookarim, 1997). 
Validity:   Means that the measurement should actually represent what it is intended to measure 
(WHO, 2001). 
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WHO Clinical Stage 1 & II of HIV/AIDS for Adults and Adolescents (PEPFAR, 2009): 
 
 
Asymptomatic 
Persistent generalized 
Lyphadenopathy 
Moderate unexplained weight loss 
(<10% of presumed or measured 
body weight), recurrent respiratory 
infections (sinusitis, tonsillitis, otitis 
media, and pharyngitis), herpes 
zoster, angular cheilitis, recurrent 
oral ulceration, papular pruritic 
eruptions, seborrheic dermatitis and 
fungal nail infections 
Stage I 
Stage II 
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ABSTRACT 
Survey on nail discoloration (ND) and association with CD4 count among untreated HIV 
patients APIN Centre Jos, Nigeria  
Peter  N    Ekeh 
MPH Mini-thesis, School of Public Health University of the Western Cape 
Background: Eligibility for antiretroviral therapy (ART) in HIV-infected patients is defined 
either by a cluster of differentiation antigen 4 (CD4) count of less than 200cells/mm3 or clinical 
diagnosis of WHO stage III and IV. Therefore, the decision to start ART becomes difficult when 
CD4 cell count is not available. With limited laboratory infrastructure, the decision to start ART 
is usually made based on clinical symptoms leading to late commencement of ART. This calls 
for alternative criteria to see if nail discoloration (ND) correlates with low CD4 count among 
untreated HIV infected patients. This will serve as a complementary screening tool for 
identifying asymptomatic ARV naive HIV patients with a CD4 cell count of less than 
200cells/mm3 which signifies severe immunosuppression. 
Study Design and Setting: This was a quantitative cross-sectional descriptive and analytical 
study involving adult ART naïve HIV infected patients in WHO stage I and II. Systematic 
sampling was used to select the participants from all adult ART naïve HIV infected patients 
attending APIN clinic, located at the Jos University Teaching Hospital (JUTH), Jos, Nigeria. 
Data Collection: Face-to-face interviews, physical examination and relevant laboratory 
investigations with selected participants were conducted using a questionnaire guide. Questions 
on socio-demographic characteristics, clinical data, general physical examinations including 
finger nail examination and photographing with subsequent laboratory investigations including 
CD4 count and western blot were employed.  
 
 
 
 
 xvii 
 
Data Analysis: Variables were categorized and data analyzed using descriptive statistics 
including the frequency, percentage frequency; mean and standard deviation of continuous 
variables. Association between CD4 count of ≤200cells/mm3 and ND was tested using the chi-
square test with an alpha level of 0.05. Prevalence of ND, sensitivity, specificity, positive 
predictive and negative predictive values and accuracy of the screening test of ND was 
calculated. 
Results: 394 patients had their fingernails photographed and assessed. It was shown that distal 
banded and grey nails were the common types of ND seen with a prevalence of 38%.  There was 
an association between CD4 count ≤200cells/mm3 and ND (p<0.0001). CD4 count 
≤200cells/mm3 was a risk factor for developing ND (RR=2.3[1.8-3.6]). The association has a 
sensitivity of 78%, specificity of 55%, positive predictive value of 50%, and negative predictive 
value of 80% and accuracy of test 63%. 
Conclusion: With a significant association (p<0.0001) and a sensitivity of 78%, ND can be a 
useful clinical indicator of immune dysfunction mediated by HIV among patients in WHO stage 
I or II. ND can either be a clinical sign or a symptom in HIV patients with a CD4 of ≤ 
200cells/mm3 as seen in the study as the specificity and sensitivity of ND compared favourably 
with other WHO stage III diagnosis. 
Recommendations: Nail discoloration should complement CD4 count as an additional staging 
sign to help identify patients likely to benefit from ART especially in resource-limited settings. 
Finally, all patients with grey or distal banded should be on co-trimoxaxole prophylaxis in line 
with WHO /national guideline on the use of co-trimoxaxole for all HIV positive patients with a 
CD4 cell count of ≤350cells/mm3.  
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CHAPTER 1 
INTRODUCTION 
1.1. Background 
 Since the first case of Human Immunodeficiency Virus/Acquired Immune Deficiency 
Syndrome (HIV/AIDS) was reported in Nigeria in 1986 (Abdusalam & Tekena, 2006), the 
number of people living with the virus has steadily increased. Nigeria has a HIV prevalence of 
4.6% (NACA, 2010). HIV/AIDS associated mortality and morbidity have continued to rise in 
spite of the efforts of the Federal Government of Nigeria (FGN) and international and local 
partners to combat the disease and HIV/AIDS continues to be a major public health concern for 
the country. It was estimated that in 2009, the annual AIDS deaths was 192,000 (male: 86.178; 
female: 105,822) (NACA, 2010). These deaths due to HIV/AIDS, has increased the number of 
orphans and decreased the size of the workforce as it affects mainly adults in their most 
productive years of life (15-49 years) (FMOH, 2005). The rate of HIV infection continues to rise 
with 336,379 new infections recorded in 2009, while an estimated number of about 2.98 million 
people live with HIV/AIDS (NACA, 2010).  In response to this challenge, the FGN, as part of its 
care and support strategy to combat HIV/AIDS, initiated the National Antiretroviral Drug Access 
Programme to improve the health and quality of life of People Living with HIV/AIDS (PLWHA) 
in Nigeria. The FGN also developed national ART guidelines which serve as a tool to equip 
clinicians to manage patients appropriately in all the tiers of the healthcare delivery system 
(FMOH, 2006). According to the National Agency for the Control of AIDS (NACA), about 
100,000 PLWHA who met the eligibility criteria were on ART in Nigeria as of December 2006 
(UNICEF, 2007). This number is far below the number of people who should be on ART. 
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According to NACA, 857,455 (adult 754,375; children103, 080) require ART (NACA, 2010) but 
were denied access because they did not meet the eligibility criteria (Onwujekwe, 2010). 
 The eligibility criteria to determine those in need of ART initiation in Nigeria, is the same 
as the WHO criteria (Table 1) and is defined as WHO Stage I or II with CD4 count of less than 
200cells/mm3; WHO stage III disease with CD4 cell count of less than 350cells/mm3 or WHO 
stage IV disease irrespective of the CD4 count (FMOH, 2005). In December 2009, the World 
health organization (WHO) updated its guidelines for the commencement of ART for adults and 
adolescents (WHO, 2010). Nigeria is yet to incorporate these guidelines into her ART treatment 
protocol but promised to do so (Personal Communication: Dr Ernest Ekong, APIN Plus/Harvard 
PEPFAR Nigeria Clinical Coordinator, 19th May 2010). According to the new ART guidelines, 
all adolescents and adults including pregnant women with HIV infection and CD4 counts ≤ 350 
cells/mm3 should be started on ART regardless of whether they have clinical symptoms (WHO, 
2010). These Nigeria/WHO criteria require laboratory assessment in order to decide ART 
eligibility. CD4 count is important in the WHO HIV clinical staging system as both clinical 
classification system and a laboratory CD4 cell count classification are used to categorize 
patients.  CD4 count assessment has been a major challenge that prevents people from accessing 
ARV’s and care from reaching many more in need, especially in rural settings where low cost 
ARV are now being offered with CD4 machine unavailable for routine use (USAID,2008). High-
quality treatment, care and prevention programs depend on effective and reliable laboratory 
infrastructure (Abimiku, 2009). Where these laboratory infrastructures are present, the cost of 
services becomes an obstacle to its use for the majority of those in need. In areas with limited 
laboratory infrastructure, the decision to start ART is often made based on clinical symptoms, 
which means that ARVs are commenced too late for the patients to derive maximum benefit.  
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         The timely initiation of ART at WHO Stage I or II disease with CD4 cell counts of less 
than 200cells/mm3 has been found to increase physicians confidence that mortality and morbidity 
rates due to progression to advanced HIV are reduced with ART (Lawn, Harries, Anglaret, Myer 
& Wood, 2008; Wolbers et al., 2008 ). In addition, it decreases expenses for palliative care and 
decreases the number of orphans as mortality from advanced AIDS is avoided (Lawn et al., 
2008; Alcorn & Safreed, 2009). 
        Until CD4 cell count testing becomes universally accessible, there is an urgent need to 
identify alternative markers of disease progression, which will assist in the identification of 
patients with WHO stage I or II diseases with CD4 cell counts less than 200cells/mm3 in 
resource limited settings. Nail discoloration (ND) is proposed to be one of such marker. If 
correlation exists between ND and CD4 count of less than 200cells/mm3, it will serve as an 
alternative marker of disease progression and will help in identifying those who are eligible for 
ART. Identifying alternative markers of disease progression is in line with WHO affirmation that 
all national and international health policies be based on valid scientific evidence (Fathalla, 
2004). 
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	Table 1: WHO eligibility criteria for commencement of ART 
 
WHO  Clinical Staging Definitions CD4 counts(cells/mm3) ART Eligibility 
Stage 1 
Asymptomatic 
<200 Eligible 
>200 Not eligible 
Persistent generalized lymphadenopathy 
Stage II  
Moderate unexplained weight loss (<10% of 
 Presumed or measured body weight. 
<200 
 
 
 
>200 
Eligible 
 
 
 
Not eligible  
 
 
 
 
Recurrent respiratory infections. 
Herpes zoster 
Angular cheilitis 
Recurrent oral ulcerations 
Popular pruritic eruptions 
Seborrheic dermatitis 
Fungal nail infections 
Stage III 
unexplained severe weight loss(>10% of presumed or 
measured body weight) 
unexplained chronic diarrhea for >1 month 
< 350 
 
>350 
Eligible 
 
Not eligible  
unexplained persistent fever for >1month 
persistent oral candidiasis (thrush)  
oral hairy leukoplakia 
pulmonary tuberculosis (current) 
severe presumed bacterial infections 
acute necrotizing ulcerative steatites, gingivitis or 
periodontitis 
unexplained anaemia(haemoglobin <8 g/dl) 
neutrophils <500cells/mL) 
chronic thrombocytopenia (platelets <50,000cells/mL) 
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Stage IV Eligible irrespective of 
CD4 count 
HIV wasting syndrome 
Pneumocystis pneumonia 
Recurrent severe bacterial pneumonia 
Chronic herpes simples infection 
Candidiasis of esophagus, trachea, bronchi or lungs 
Extra pulmonary tuberculosis 
Kaposi sarcoma 
Cytomegalovirus infections 
Central nervous system toxoplasmosis 
HIV encephalopathy e.t.c 
Source: PEPFAR/Harvard School of Public Health, Adult Antiretroviral Treatment Protocol version 2.0, 2009. 
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1.2. Problem Statement and Study Rationale 
         Most physicians working in APIN clinic, JUTH had observed that several HIV infected 
patients in WHO stage I or II presented to the adult ART clinic with ND. During physical 
examination it was found that the nail colours were grey, half and half grey or blue or distal 
banded nails. These observations, led to the comparison of these nail features with the patients 
CD4 count level and it was found that several patients had a low CD4 less than 200cells/mm3.  
This observation served as the motivating factor for conducting this research. This 
research would complement CD4 count testing which was a necessary diagnostic tool in 
determining the eligibility criteria for the commencement of ARV’s. Factors ranging from other 
medical conditions, trauma and local nail dye application could influence the cause of ND 
among HIV patients. Patient’s history, physical examinations and relevant laboratory 
investigations would help in associating its correlation with HIV and low immunity. That meant 
that all HIV infected patients would be examined for ND and CD4 count tested for possible 
association while other factors that could cause ND could be ruled out. If correlation exists and a 
screening tool is created, it would help to reduce the number of HIV patients presenting in WHO 
stage III and IV and also the burden associated with their management. It would save cost in the 
management of HIV patients who could not afford the cost of travelling to urban areas for a CD4 
count testing. Finally the difficulty encountered in taking blood samples from the rural areas to 
urban areas for CD4 count testing will be reduced. 
1.3. Description of Research Setting 
 This research was carried out at the Harvard/U.S President Emergency Plan for AIDS 
Relief (PEPFAR)/APIN Clinic, Jos University Teaching Hospital (JUTH) Jos, Plateau State, 
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North Central Nigeria. It is a tertiary, referral hospital serving six states (Plateau, Nasarawa, 
Benue, Bauchi, Taraba and Gombe) with a total population of 18,592,311 (NPC, 2006).These 
states are made up of different ethnic groups. Hausa is the common language spoken and the 
major ethnic group. The clinic is one of the major sites where the free ART programme of the 
United States government through the APIN/Harvard PEPFAR is being implemented in Nigeria 
and has 19,000 patients with Male:Female ratio approximately 1:2, in its care as at October 2009 
(Personal Communication: Dr Patricia Agaba, APIN Site Coordinator,11th November 2009).    
  The economic base of the majority of the people that patronize the clinic is farming; 
while civil servants, the military, paramilitary, business community and petty trading make up a 
small proportion of other users. All of its services (drugs, laboratory and clinical) are free. The 
laboratory is presently undergoing Centre for Disease Control and Prevention (CDC) assessment 
in preparation for WHO accreditation (Personal communication: Mr. Godwin Imade, APIN 
Laboratory Manager, 20th May 2010). It is the only laboratory within the north central zone fully 
equipped by PEPFAR for effective management of HIV/AIDS and research (Personal 
communication: Mr. Godwin Imade, APIN Laboratory Manager, 20th May 2010). The laboratory 
was staffed with trained laboratory scientist and carried out all necessary investigations required 
for the effective management of HIV. HIV services are being scaled-out to secondary and 
primary health care institutions together with laboratory services. The programme has three 
clinics, the pediatrics, maternity (PMTCT) and the adult antiretroviral units.  
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1.4. Study Objectives 
1.4.1. Aim 
 To investigate the prevalence of nail discoloration among untreated HIV infected 
patients, its association with CD4 cell count and its potential For use as an indicator for the 
initiation of ART 
1.4.2. Specific Objectives 
1. To determine the prevalence of nail discoloration among untreated HIV infected patients 
presenting at the APIN clinic, Jos University Teaching Hospital. 
2. To characterize the type of nail association in untreated HIV infected patients presenting 
to the APIN clinic at the Jos University Teaching Hospital, Nigeria. 
3. To determine the Positive Predictive Values (PPV), sensitivity and specificity of nail 
discoloration with CD4 levels. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1. Anatomy of the Nail 
 Anatomically fingernails are made up of a tough protein called keratin and have many 
different parts, namely: cuticle, nail plate, nail fold, lunula and nail bed (Fig.1). Among the 
important parts are the nail plate and the lunula. The nail plate is the hard and translucent 
portion, composed of keratin underlined by a pink nail bed which is due to its rich vascular 
network (DermWeb, 2009), while the lunula is the crescent shaped whitish area of the nail bed. 
Functions of the fingernails include: Protecting the distal phalanx from trauma, helps in picking 
up small objects, aids in the appreciation of fine touch, used for scratching and aesthetic organ. 
 The growth of the nails is continuous throughout life and it is 0.5 to 1.2mm per week 
(Derm Web, 2009). The nail color changes are classified according to whether these occur in 
morphology (shape) or color of the nail (Gregorion, Argyrion, Larios & Rigopoulos, 2008).  
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Figure1: Normal fingernail 
 
2.2. Causes of Nail Discoloration 
 The nail is part of the skin but it is not located in the dermis but in the fingers and toes 
(Choi, 2002), so nail discoloration is a skin disorder. Daniel (1985) summarized the causes of 
nail discoloration into four different categories of pigmentation abnormalities: 
1. Changes attributable to other systemic diseases. These include diseases that involve 
organs which can cause changes in the nails as well. For example kidney failure, cirrhosis 
of the liver and HIV infection. 
2. Changes caused by systemic drugs or ingestants. Different drugs or ingestants can lead to 
discoloration of nails, which usually gets better after the drug is stopped. For example 
blenoxane, chloroquin, minocycline, Highly Active Antiretroviral Therapy (HAART) 
like zidovudine, entricitabine and severe arsenic poisoning (Levay, Botes & Malela, 
2005). 
3. Changes attributable to local agents such as nail dyes and other topical agents. 
Nail plate
Nail fold
LunulaCuticle 
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4. Changes attributable to some nail entities. People with separation of the nail plate from 
the nail bed or complete nail plate loss are at risk of infection with fungus leading to ND. 
   It is increasingly acknowledged that the nail and systemic diseases are interconnected and 
that nails can provide valuable diagnostic or screening clues to underlying pathologic conditions, 
such as HIV and AIDS (Daniel, 1985; Starrianeas et al., 1993 & Gregorian et al., 2008). Nail 
changes are classified according to morphology or color of the nail (Gregorion et al., 2008).  
       Scarborough et al. (2006) and Gregorion et al. (2008), described distal banded nail as a 
situation where most of the nail plate is white, with a narrow pink or transverse band of darker 
than normal nail pigmentation of 1 to 3mm in width in the distal nail bed. All the nails tend to be 
uniformly affected. This type of nail is sometimes referred to as half and half nails where the 
proximal portion of the nail bed is whitish because of edema of the nail bed and capillary 
network; distal portion is pink and reddish brown. The nail plate of the patient is unaffected. This 
type of nail disorder is found in patients with HIV infection and among patients with cirrhosis of 
the liver, chronic congestive heart failure, haemodialysis and renal transplant recipients 
(Gregorion et al., 2008).              
              Other conditions like heart failure may cause pink nails, while yellow nails may result 
from lymphatic obstructions and white nails may suggest a chronic liver disease or renal failure 
(Rehmus, 2007). Grey nail has also been shown to result from HIV infection (Scarborough et al., 
2006). 
         Longitudinal pigmented bands on the nail (brown-black nail) can be found in 77% of 
people of the black race (Woo & Sibbard, 2007). These bands are regular and extend from the 
proximal nail fold to the distal tip of the nail. Transverse lines on the nail occur in 7.1% of cases, 
while leukonychia or white nails (white discoloration appearing on nails) occur in 14.3% of 
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cases and longitudinal melanochia occur in 14.8% of cases of untreated HIV patients (Cribier et 
al., 1998). Bluish or grey color of the nail bed is said to have a prevalence of 19% among 
untreated HIV patients (Levay, Botes & Malela, 2005). These nail color changes has been a 
useful tool in determining CD4 count level as these studies (Panwaker, 1987; Cribier et al., 1998; 
Levay, Botes & Malela, 2005, Woo and Sibbard, 2007 & Namakoola et al., 2010) correlated 
them with immunosuppression. Other causes of nail color changes include; chemotherapy such 
as blenoxane, silver, minocycline; severe arsenic poisoning, zidovudin, drug hypersensitivity 
reaction such as tetracycline and fluconazole. Diseases/infections like Plummer-Vinson 
syndrome, iron deficiency anemia, fungal and pseudomonas infection, atopic dermatitis, 
jaundice, lichen planus, psoriasis, yellow nail syndrome, onycholysis, senile ischemia, 
malnutrition and chronic lung disease are also known causes of ND (Rehmus, 2007). These 
diseases or infections causing ND are common among HIV patients in WHO stage III and IV 
(table 1). Tobacco use and trauma have also been linked to cause ND (Gregorion et al., 2008). 
2.3. Nail Discoloration, Human Immunodeficiency Virus and Cluster Differentiation of 
Antigen 4 Count  
      Skin disorders are commonly encountered in HIV infected patients and may be the first 
manifestation of HIV disease. This skin is more likely to have an unusual appearance among 
those with advanced AIDS (Tse, 2007). Up to 90% of HIV infected persons suffer from skin 
diseases during the course of their illness. Out of these, nail disorders constitute up to 10% and 
are more prevalent in the elderly (Woo & Sibbald, 2007). Factors like immune depression and 
concurrent use of HAART have led to the high prevalence of skin disorders (Personal 
communication: Dr Ekpudu Violet, Consultant Dermatologist, and 10th March 2009). Others 
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include the pattern of endemic infections, impaired circulation and concurrent chronic illness 
such as Diabetes Mellitus (Glaser & Remlinger, 1996). The prevalence of skin diseases may vary 
with one’s geographic location (Tse, 2007).  Infection with HIV leads to a chronic and, without 
treatment, usually fatal infection characterized by progressive immunodeficiency with or without 
long clinical latency period and associated opportunistic infections. The hallmark of HIV disease 
is infection and viral replication within T- lymphocytes expressing the CD4 antigen (Sax, Cohen 
& Kuritzkes, 2010). Cell mediated response are of two types, the CD4 cells (helper cells as it 
activates and coordinates other cells of the immune system) and the CD8 (suppressor cells) 
which destroys cells infected by bacteria and viruses.  
          CD4 cells are a critical component of normal cell mediated immunity. The CD4 cell is an 
indication of the T-helper cells in the blood and is a subset of the lymphocytes which gives a 
reflection of the strength and weakness of the immune system in the body and a predictor of the 
rate of development of opportunistic infection in the body. A report in Nigeria has found CD4 
cell counts in healthy Nigerians to range from 636cells/mm3 to 977cells/mm3 (Olaleye, Harry & 
Odaibo, 2006). Once in the body, HIV attaches to helper T-lymphocytes whose surface has a 
receptor called CD4 which enables HIV to attach to them. Inside this CD4 cells, HIV uses the 
lymphocytes’ own genetic machinery to reproduce itself leading to the destruction of the 
lymphocytes and subsequent weakening of the body’s immune system which protects against 
infections and cancers. Without treatment, the average time for acquisition of HIV to an AIDS-
defining opportunistic infection in 90% of people infected with HIV is less than 10 years (Sax, 
Cohen & Kuritzkes, 2010; Lynen, 2008). Individual variability in these time intervals exists as 
some patients may progress from acute HIV infection to death within 1-2 years and some for 
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greater than 10 years (Sax, Cohen & Kuritzkes, 2010). One of the steps to a successful ART is to 
diagnose and treat before the immune system is severely suppressed.  
 There has been limited research on CD4 count correlation with ND and these studies 
correlated ND with immunosuppression (Cribier et al., 1998; Levay, Botes & Malela, 2005; 
Scaborough et al., 2006; Woo & Sibbard, 2007; Namakoola et al., 2010). No similar study about 
this correlation has been conducted in Nigeria, although on the African continent (Malawi, South 
Africa and Uganda), similar studies have been conducted (Levay, Botes & Malela, 2005; 
Scaborough et al., 2006; Namakoola et al., 2010) and screening tool developed (Scaborough et 
al., 2006).  
         Scaborough et al. (2006) reported the relationship between ND in HIV untreated patients 
and their level of CD4 cell count in a cross-sectional study in Malawi. A total of 222 patients 
with a mean age of 34.2 years participated in the study and had all their nails photographed. Grey 
or distal banded nails were significant (p<0.0001) and when compared with the control (pink 
nails), grey or distal banded nails was strongly associated with a CD4 count of less than 
200cells/mm3 (Scaborough et al., 2006). The sensitivity was 56%, specificity of 85% and a 
positive predictive value of 81%. The researchers concluded with a recommendation for 
clinicians working in sub-Saharan Africa without access to CD4 cell count testing, that grey or 
distal banded nails represent an additional staging sign to help identify a subgroup likely to 
benefit from ART without access to CD4 count (Scaborough et al., 2006). Though the sensitivity 
was low (56%), the researcher argued that it is so with all clinical markers of HIV progression. 
The study produced a classification system for ND (screening tool) as part of recommendations 
for use by clinicians working in sub-Saharan Africa without access to CD4 cell count testing. 
The study did not produce prevalence for ND and did not mention how confounders such as age 
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and sex were controlled for and how they were able to arrive at “normal” or “grey/distal banded” 
nails. Since what was described as “grey/distal banded” nails could be a normal nail for that 
patient who must have had it prior to contacting HIV infection.  
 Namakoola et al., (2010) in a cross-sectional study was able to establish the association 
between grey/distal banded nails and immunosuppression when he evaluated the use of 
grey/distal banded nails as an indicator of advanced immunosuppression, and thus eligibility for 
ART, in resource poor settings. He found that grey/distal banded nails were significantly 
associated with a CD4 count of ≤200cells/mm3 (P<0.001) but no association with CD4 count of 
cut-off of ≤350cells/mm3.Because of the low sensitivity (66%), the study did not recommend the 
use of grey/distal banded nails as a tool to a guide ART initiation; as large number of patients 
eligible for ART will be missed. The results also had a specificity of 50% and a negative 
predictive value of 77%. 
 Levay, Botes & Malela (2005) defined Dyschromonychia (DCO) as the total absence of 
the nail lunula with the presence of a bluish-grey discoloration of the nail or nail bed. It is a term 
generally applied to patients with increased nail pigmentation. A form of ND, DCO was found to 
be associated with HIV in a study that was to determine the association with HIV and DCO 
(Levay, Botes & Malela, 2005). This study had a hypothesis that DCO was a predictor of 
advance immunosuppression in HIV disease and was carried out at the immunology clinic. It 
was a prospective observational study. A hundred consecutive clinic patients were evaluated by 
three doctors. The prevalence of DCO was 19% at the immunology clinic and 52% (probably 
due the advanced HIV/AIDS infection) for those admitted in the ward with associated 
immunosuppression (Levay, Botes & Malela, 2005). All the finger nails were equally affected in 
7.25% of cases but the nails involved most commonly were the thumb and the ring finger 
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(Levay, Botes & Malela, 2005).With this prevalence, they concluded that there was a close 
association between HIV and DCO in the case of low CD4 count and that the presence of DCO 
has a high sensitivity for HIV sero-positivity otherwise serving as a screening tool. That the 
clinical findings of DCO is simple, quick and efficient sign for the evaluation of the immune 
status of HIV population with reasonable sensitivity (66%) and specificity (92%) for low CD4  
count (Levay, Botes & Malela, 2005). Considering the study design used (prospective study), 
patients were supposed to be followed when there were no DCO and observed when they start 
having DCO. This perhaps would have taken a longer time. This study design was not supposed 
to give us the prevalence of DCO. These patients were chosen at a particular point in time at the 
clinic and the ward with a prevalence of DCO, these indicates that it was a cross sectional study. 
If the original study design was followed, these would have helped to determine the precise risk 
factor, even though it was expensive and time consuming. On the use of three doctors for 
evaluation of the patient with DCO, the study did not address the method of DCO identification 
as determining DCO is subjective and thus will increase the rate of measurement bias.  
Cribier et al. (1998) in a prospective cohort study carried out in an HIV care centre, 
France to study the frequency of nail changes in a population of HIV infected patients examined 
and photographed all the patients’ nails. A total of 155 untreated HIV-1 positive and 103 healthy 
HIV negative controls were recruited. Out of these, ND was present in 67.7% of HIV positive 
patients and was linked with immunosuppression (Cribier et al., 1998). Results show nail 
symptoms of transverse lines (7.1%) and longitudinal melanochia (14.8%) more frequent among 
the HIV positive group than healthy controls (Cribier et al., 1998).  The study did not correlate 
the ND with the level of CD4 cell count like Levay, Botes & Malela (2005) and did not mention 
how the sample number and selection was made. Cribier et al. (1998) in his conclusion 
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emphasized a systematic nail examination of HIV infected patients and advocated for further 
studies correlating ND with levels of immunosuppression.  
          Rizos, Drosos & Ioannidis (2003) in their case report, observed that during physical 
examination in an untreated HIV patient in Greece, they found nail pigmentation with a CD4 cell 
count of 116 cells/mm3 which they associated  with HIV  following patients history and 
laboratory investigations they conducted. This report was descriptive in nature and could not 
describe the association between the pigmented nail and HIV. Nagalingeswaran et al. (2000) 
examined the type of dermatologic findings including nail changes present among HIV infected 
patients in an AIDS research and education centre in India. A total of 833 HIV patients were 
examined. Eighteen (18) untreated patients had black colored nails with varying degrees of 
immunosuppression present. The study could not give the degrees of immunosuppression 
present.   
          Many articles agreed that distal banded nails or half and half nails were associated with 
HIV (Gregorion, Argyrion, Larios & Rigopoulos, 2008; Chadrasekar, 1989). Beau’s line, a form 
of ND, in association with pallor of the nail beds was said to be a general effect of chronic illness 
and has been associated with HIV and can serve as a pointer to severe immunosuppression 
(Erdal, Zalewska, Schwartz & Hamadeh 2007; Daniel, Norton & Scher, 1992; Pros, Abson, 
Scher, 2007). Also, nail color changes such as yellow discoloration of the distal part of the nails 
and hyper pigmentation showed a statistically significant correlation with HIV and 
immunosuppression (Sindrip, Lisby, Weismann & Wantzin 2007; Dover & Johnson, 1992; 
Smith et al., 1994; Reynaud-Mendel et al., 1996; Matis, et al., 1987; Aftergut, 1999; See & 
Wong, 1992; Chernosky & Finley, 1985). 
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         In conclusion various studies have correlated different types of ND with 
immunosuppression with significant findings (P<0.001) and recommendations were made. With 
prevalence of ND (distal banded, grey or DCO) in HIV infected patients ranged from 19% 
(Levay, Botes & Malela, 2005) to 67% (Cribier et al., 1998). Scaborough et al. (2006), 
Namakoola et al. (2010) and Levay, Botes & Malela (2005) had ND sensitivity of 56%, 66% and 
66% respectively. Sensitivity was for all the population with ND, these results were not too 
good, and that means that some people with ND were missing in the population. This does not 
mean that the sensitivity should be rejected as it is still better than a random guess. Specificity of 
85% (Scaborough et al., 2006) and 92% (Levay, Botes & Malela 2005) was looking at those 
population without ND and these figures suggested a good specificity. A positive predictive 
value of 81% (Scaborough et al., 2006), though not too good but it was still better than chance as 
it only gave those with ND in the population. Population groups in Nigeria have not been 
previously assessed for association of ND with CD4 cell count. This study intends to investigate 
the prevalence of ND among untreated HIV patients and if HIV untreated patients with ND have 
an association with low CD4 cell counts. 
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CHAPTER 3 
 METHODOLOGY 
3.1. Study type/design 
The study was based on a quantitative cross-sectional descriptive and analytical study. It 
involved the description of types of ND among adult ART naïve HIV patients in a HIV clinic in 
Jos, Nigeria and analyses were carried out to identify if there was association of ND and low 
CD4 count.   
3.2. Study population 
 The study population involved all ART naïve HIV infected adult patients in WHO stage I 
and II (Table1) attending the APIN clinic at JUTH, Jos in Nigeria. All study participants were 17 
years of age and above. After applying exclusion criteria (those whose nails could not be 
evaluated due to trauma, dystrophy or nail polish and those patients already in WHO stages III & 
IV [see table1], histories of prior exposures to HAART), 394 patients remained to serve as the 
sampling frame (source population). 
3.3. Sample size 
The minimum sample size of 392 participants was calculated using Open Epi version 
2.2.1 computer programme (Dean, Sullivan & Soe, 2009) assuming a  significance level of 0.05, 
a hypothesized ND prevalence of 19% (Levay, Botes & Malela, 2005) with a total patients 
attendance of  19,000 since the inception of the clinic 5 years ago (APIN clinic record as at 
October, 2009). However to take care of refusal by some clients to participate, non-response or 
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incomplete data, questionnaire was administered to 439 participants who consented to research, 
clinical examination and laboratory investigations were evaluated done.  
 
3.4. Sampling procedure 
The clinic presently enrolls 0 to 18 new patient’s daily (Clinic enrollment register from 
January to April 2010). After applying the exclusion criteria, 439 subjects were systematically 
selected from a population of 1260 who presented at the clinic from the 3rd May to 16th of July. 
The patients who presented daily for enrollment into the HIV treatment and care program had 
undergone a voluntary HIV screening at the APIN voluntary counseling and testing centre or 
were referred from other sites. At the APIN clinic, these patients were allowed to pass through 
the normal clinic enrollment procedures which involved obtaining hospital numbers, group post-
test counseling on HIV, taking of vital signs and sorting of patients based on clinical presentation 
in order that those who were too sick were given urgent attention in line with the routine health 
services provision in the clinic.  
 After the normal clinic procedures, patients were taken to see the two doctors for pre-
assessment which involved history-taking, clinical examination and laboratory evaluation. The 
pre-assessment level was the first contact of the patients with the investigator or interviewer. A 
random starting point from 1 and 1260 was selected in order to determine the starting point. With 
a sample interval of 3, every third person that presented to the investigator was selected until the 
required sample size was obtained. The two interviewers in their consulting rooms requested 
patients to participate in the study and interviewed them after they offered consent. Any patient 
with a visible exclusion criteria (WHO stages III and IV, painted, dystrophic or traumatic nails), 
was not requested to participate. Those with clinical findings (past histories of haemodialysis, 
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nail painting or smoking) and laboratory findings (negative Western blot, liver or kidney 
derangement, diabetes mellitus) with link to ND were regarded as indeterminate and excluded 
from analysis. Patient attrition was not anticipated in this study, since it was cross-sectional. 
3.5. Data collection and processing 
Data was collected through face-to-face interviews with patients who gave consent and met the 
inclusion criteria. Two medical doctors (who were part of the doctors involved in the pre-
assessment of patients in the APIN clinic) who participated in the study were selected based on 
qualification, interest in participating in the research and the ability to use a camera. They were 
briefed on why the study was being conducted and trained on how to use the digital camera for 
taking clear photos and on how to administer the questionnaire. The student investigator did not 
take part in data collection in order to ensure that bias was not introduced. A structured 
questionnaire (Appendix 3) was administered by the clinicians. The questionnaire contained two 
parts (sections A and B). Section A captured the patient’s demographic profile. While section B 
captured the patient’s medical history including their current health and medication, physical 
examination findings and laboratory investigations such as CD4 count and Western blot for HIV 
infection confirmation. As the patients present to the clinic, their fingernails were photographed 
after hand washing with antiseptic soap and water using a bright indoor daylight with a digital 
still camera by the trained clinicians. All photographed nails were passed round to four selected 
clinicians (blinded to patient identity) in APIN clinic for identification of various nail colors 
using the nail color chart produced by Scaborough et al., 2006.  
 . These clinicians (could be doctor, nurse, pharmacist or a counselor) had their names 
written on a piece of paper and were randomly handpicked. All the four clinicians agreed that 
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normal nail color and ND (grey or distal banded) existed 394 clients. Other inconclusive findings 
(dystrophic, nail polish, smokers, laboratory findings suggestive liver, renal disease or diabetes 
mellitus linked to ND or a negative western blot result, poor photographing[early part of the 
study when the use of the camera had not been mastered] and discordant nails colors among 
clinicians) was also recorded as indeterminate (Fig.2-4) and excluded from the final data 
analysis. Nail colors were recorded as pink (normal), distal banded, grey or indeterminate nails. 
Information from the questionnaire was entered into an Epi info 3.5.1 database (CDC, Atlanta, 
Georgia, USA) for analysis. 
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Figure 2: Indeterminate (painted) nails. Painted nails due to cosmetics (left) and local nail paints 
(right) 
  
Figure 3: Indeterminate (infected) nails. Infected nails with abnormal nail plate and bed. 
 
Infected nails
 
 
 
 
 24 
 
 
Figure 4: Indeterminate nail (poor photographing). Distal banded nails with poor photographing 
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3.6. Validity 
A study can be said to be valid if its results corresponds to the truth (Beaglehole, Bonita 
& Kjellstrom, 2006). To ensure validity, sample size was calculated with a required level of 
statistical significance of the ability to detect a difference, the amount of the disease in the 
population and the size of the group being compared using Open Epi version 2.2.1 computer 
programme (Dean, Sullivan & Soe, 2009). Systematic sampling was used to obtain the sample 
size from the sampling frame in order to reduce selection of participants. Literature review and 
inputs from the clinicians was used to develop the questionnaire to ensure both validity and 
reliability of the study and the comparability of result across studies.  
Confounders were controlled by restricting the study to only the HIV positive HAART 
naïve population enrolling at the clinic and the exclusion of those HIV patients with causes of 
ND identified by Daniel (1985). These changes included those attributable to other systemic 
diseases like kidney failure, diabetes or liver problems; changes caused by systemic drugs or 
ingestants like azidovudine (AZT) and emtrcitabine; changes attributable to local agents such as 
nail dyes and other topical agents; Changes attributable to some nail entities like those patients 
with separation of the nail plate from the nail bed. Other potential confounders that were 
measured included patient’s age and gender. The sensitivity, specificity and positive predictive 
value of the test was calculated to determine the usefulness of ND. 
3.7. Reliability 
In order to ensure that someone else repeating the test using the same method should be 
able to obtain the same findings pilot testing of the questionnaires was undertaken. Clinicians 
enrolling patients were trained for proper identification and photographing of fingernails using 
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the nail color chart produced by Scarborough et al. (2006) as a guide. The clinicians were 
encouraged to sign their names on the questionnaire in order to ensure accurate work and make 
checking of records much easier. The patients were allowed to pass through the normal clinic 
procedures and were treated like any other patients for laboratory investigations, thereby 
ensuring that the laboratory scientists have no (prior) knowledge of the study. The identified and 
photographed ND from the clinicians was printed for other clinicians to identify the nail colors. 
Only the nail colors easily identified was used and others recorded as indeterminate. 
 Measurement errors due to individual biological variations was not a trait as the study 
was conducted with people of skin color similar to the Malawi study (Scaborough et al., 
2006).The Malawi study was carried out among patients of Fitzpatrick skin color of type IV. 
This is the color of skin shared among the black race (Derek, 1981 & Sachdeva, 2009), thereby 
ruling out errors resulting from individual biological variations. 
3.8. Generalisability (External Validity) 
 Every individual race has a unique skin color type. For the black race, they share a 
common skin color type known as Fitzpatrick skin color type IV (Derek, 1981 & Sachdeva, 
2009). All the adult ART naïve HIV infected patients attending APIN clinic belong to the black 
race, therefore, the study is only generalisable among the people of the black race. 
3.9. Ethical Considerations 
   This study was approved and endorsed by the Higher Degree Committee of the 
University of the Western Cape in South Africa. Ethical clearance was then received from the 
Jos University Teaching Hospital/Human Research Ethics Committee (Appendix 4). 
Subsequently, final permission to conduct the study at the APIN clinic was received from the 
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APIN clinic research committee (Appendix 4). The nature of the study and participant 
information sheet (Appendix 1) was introduced to the prospective study participants by the 
respective interviewer. All patients consented to the research (see consent form, Appendix 2) by 
signing or thumb printing in line with the Helsinki declaration (WHO, 2001). Three patients 
were not up to 18 years. They accented to the study, while their parent consented for their 
participation. Patient’s clinical management was not affected. 
  For patients having nail infections or other health conditions that was not clinically 
apparent to them appropriate referral for treatment was made. There were no physical or 
psychological harmful effects to participants that were expected from this study.  The documents 
assured privacy and confidentiality of information collected from participants. The documents 
also assured the participants of their rights to withdraw from the study or refuse to participate in        
the study.                       
 The researcher ensured that human subject were fully protected, responsibly conducted 
the research in line with good clinical practice following the guidelines provided by the 
Collaborative Institutional  Training Initiative (CITI) , University of Miami, U.S.A. in 
collaboration with WHO (Appendix 6). Patient’s data were collected and used anonymously; 
questionnaires were locked in a safe place accessible to the researcher only. 
3.10. Data Analysis 
3.10.1. Data Handling and Cleaning 
 Questionnaires were constantly checked during data collection to correct any query 
especially errors in data collection that arose. Questionnaires helped solve any query that arose 
during exploratory data analysis. Two separate views were created in Epi info version 3.5.1 (CDC, 
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2008) and the data from the questionnaires entered by two persons (the investigator and a 
statistician). The two entries were compared and any discrepancies such as double entries or strange 
values (outliers) were investigated. Using the Epi Info data analysis, all the variables were listed. 
Entries were compared again for any discrepancies. When implausible variables or values were 
obtained, the respective questionnaire was re-visited and data correction effected. Any value which 
could not be corrected by referring to the questionnaire was recorded as missing. Sixteen 
questionnaires were not entered for analysis as a result of unsigned consent forms or incompletely 
filled where vital information like age, sex were missing. This helped in reducing errors arising 
from measurement. This was followed by exploratory graphical data analysis and the exclusion of 
31 indeterminate results including nails (Fig.2-4) before subjecting the data for real analysis. Data 
analysis was then carried out on a sample size of 394 respondents. 
3.12.2. Variable Categorization 
 The categorization of variables was informed by the WHO updated guidelines. In terms 
of which all adolescents and adults including pregnant women with HIV infection and CD4 
counts ≤ 350 cells/mm3, should be started on ART regardless of whether they have clinical 
symptoms or not (WHO, 2010). Two cut-offs: CD4 count ≤200 and ≤350 cells/mm3 was 
analyzed. This analysis employed both dichotomous variables and those that had more than two 
categories. The dichotomous variables were gender (male and female), ND (yes or no), ND with 
CD4 ≤ 200 cells/mm3 (yes or no) and ND with CD4 ≤350 cells/mm3 (yes or no). The results of 
the computation fell into six groups: positive change (ND) in nail color with CD4 count, positive 
change in nail color with CD4 count ≤200cells/mm3 and positive change in nail color with CD4 
count ≤350cells/mm3, negative change (no ND) in nail color with CD4 count, negative change in 
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nail color with CD4 ≤200 cells/mm3 and negative change in nail color with CD4 ≤350 cells/mm3. 
Those who had a positive change were characterized as “yes” for the variable CD4 count, while 
those who had no color change were characterized as “no” for the variable. 
 Furthermore, to allow for group comparison of these data, age, highest level of education 
attained and occupations were all categorized. The age groups for the variables were 15-24, 25-
34, 35-44, 45-54, 55-64, 65-74 and ≥75. The other variables groups were Highest level of 
education attained (no formal education, primary, secondary and post secondary education) and 
Occupation (Employed [farmer, civil servants, self employed], Unemployed [applicants i.e those 
looking for job] and others [students, house wife’s, clergy, politician, politicians and business]). 
Finally, the nail color changes were categorized as normal nail color, distal banded or half and 
half nail, grey nails and indeterminate nails.  
3.12.3. Descriptive, Analytical and Epidemiological Statistics (prevalence, sensitivity, 
specificity, positive predictive values and relative risk) 
 Descriptive analysis was conducted to structure the data, explore and describe the sample 
variable composition. Frequency tables for categorical variables like sex, ND (yes or no), ND with 
CD4 ≤ 200cells/mm3 (yes or no) and ND with CD4 ≤350 cells/mm3 (yes or no) and summary 
statistics for quantitative variables like age were made. Frequency tables of ND among various age 
groups and the types of nail colors were made. Also explored was the type of distribution of the 
different variables in the dataset. Mean and standard deviation of continuous variable was 
calculated. The CD4 was skewed hence the median and the inter quartile range were used to find 
the distribution while the mean and the standard were used for the age distribution since age had a 
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normally distribution. The association between ND and CD4 count was tested using the Chi-
squared test when the expected cell values were less than 5.  
 The prevalence of ND and CD4 count of ≤ 200 and 350 cells/mm3 in the population was 
calculated. This was followed by a screening test analysis to identify if ND could be a danger sign 
of immunosuppression in a HIV patient in WHO stage I & II. Four possible combinations were 
used. These combinations were: ND may either be present or absent, CD4 cell count less than 
200cells/mm3 or 350cells/mm3 may either be positive or negative with ND. This was further 
categorized as:  
 True positive (TP) : When ND is present and the test is positive (CD4 count ≤200 or 350 
cells/mm3) 
 True  negative (TN) : When ND is absent and the test is negative (CD4 count ≥200 or 350 
cells/mm3) 
 False positive (FP) : When ND was absent and the test is positive (CD4 count ≤200 or 350 
cells/mm3) 
 False negative (FN) : When ND was present and but the test result was negative (CD4 count 
≥200 or 350 cells/mm3) 
 These categories (TP, TN, FP and FN) were used for screening tests analysis to identify 
those that have ND and those without ND. The 2 x 2 table was used for comparison of test 
classification of those with ND (positive) and those without ND (negative). With 2 x 2 tables 
those who had ND (TP) and those without (TN) was identified and their sensitivity and 
specificity calculated. Those who were positive to ND had their PPV calculated to determine 
how believable the positive test was and NPV calculated to determine how believable the 
negative test was. Since 2 x 2 table looks at already existing disease, Prevalence was calculated 
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from the table. Looking at the overall 2 x 2 table, Accuracy was calculated to determine how 
correct the screening test results were. Accuracy looks at the overall test (TP, TN, FP and FN) 
rather than one column of the table. Accuracy is expressed mathematically as:  

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CHAPTER 4 
RESULTS 
4.1: Demographic characteristics of study participants 
 This study analysis consisted of 394. All study participants were 17 years of age and 
above. The mean (SD) age of the study participants was 33.1 (8.8) years. Most of the study 
participants fell into the age group 25-44 years while a minority was aged above 65 years. There 
was no difference between the age composition of the sample to that of the overall population of 
HIV patients who attend APIN clinic (P>0.05). The study sample demographic characteristic is 
presented in table 4.2 and 4.3, while table 4.4 shows the distribution of nail colors. Nail color 
distribution among participants with respect to level of education and occupation was explored 
(Table 4.5 and 4.6). 
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Table 4.2. Age distribution of study participants  
Characteristics n (%) P-value 
Sex  
 
Mean age (SD) 
 
Males 
 
Mean age (SD) male 
 
Female  
 
Mean age (SD) female 
 
Age group(yrs) 
 
 
33.1 (8.8%) 
 
137 (34.8%) 
 
37 (9.4%) 
 
257 (65.2%) 
 
30.7 (7.1%) 
 
Males(n=137) 
 
 
 
 
 
 
 
 
 
 
 
 
Females(n=257) 
 
 
0.7 
 
 
 
0.9 
 
 
 
0.1 
15-24* 
 
6 (4.4%)                      47 (18.3%) 
 
 
25-34* 
 
52 (38%)                     133 (51.8%)  
35-44* 
 
45 (32.8%)                  52 (20.2%)  
45-54 
 
24 (17.5%)                  20 (7.8%)  
55-64** 
 
8 (5.8%)                      4 (1.6%)  
65-74** 2 (1.5%)                      1 (0.4%)  
*Age group 15-44 formed most of the sample with the females being the majority. 
**55-74 were the least age group in the sample. 
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Table 4.3: Demographic characteristics of study participants compared with those of APIN 
Clinic 
Highest level of  education 
attained  
 
 
 
No education 
 
Primary education 
 
Secondary education 
 
Post secondary education 
 
  
Occupation  
 
Employed  (Farmer civil servants) 
 
Unemployed (applicant)  
 
Others ( artisans, business, students 
e.t.c) 
n (%) 
 
394 
 
 
65 (16.5%) 
 
67 (17%) 
 
146 (37.1%) 
 
116 (29.4%) 
 
 
 
 
168 (42.6%) 
 
24 (6.1%) 
 
203 (51.2%) 
 
 
 
 
APIN Clinic n (%)         P-value 
 
19000 
 
 
3458 (18.2%)                       .50  
 
4009 (21.1%) 
 
7980 (42%) 
 
3553 (18.7%) 
 
 
 
 
8930 (47%)                         .50 
 
1406 (7.4%) 
 
8664 (45.6%) 
Year of HIV diagnosis 
2005 
2006 
2007 
2008 
2009 
2010 
 
3 (0.8) 
9 (2.3) 
29 (7.4) 
123(31.2) 
176 (44.7) 
54 (13.7) 
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Table 4.4: Distribution of nail colors 
Characteristics   n (%) P-value 
Without ND 245 (62.2%)  
With ND 149 (37.8%) 0.0001 
 
 
 
Table 4.5. Level of education and distribution of nail colors 
Nail color None  Primary  Secondary  Post secondary 
Without ND 52 (80%) 47 (70.1%) 77 (52.7%) 69 (59.5%) 
Distal banded 7 (10.8%) 8 (11.9%) 41 (28.1%) 25 (21.6%) 
Grey nails 6 (9.2%) 12 (17.9%) 28 (19.2%) 22 (19%) 
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Table 4.6. Occupation and distribution of nail colors 
 
Nail colors Farmers  Civil 
servants 
Students  Applicants Business  Others  
Without nail 
discoloration 
46(%) 47(46.6%) 29(61.7%) 16(66.7%) 23(71.9%) 84(68.3%) 
Distal banded 15(22.4%) 31(30.7%) 11(23.4%) 4(16.7%) 4(12.5%) 16(13%) 
Grey  6(9.0%) 23(22.8%) 7(14.9%) 4(16.7%) 5(15.6%) 23(18.7%) 
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 4.2. Nail Characteristics 
 The study participants nail colors were classified as those with normal nail colors, those 
with distal banded nails (popularly called half and half nail in the clinic) and grey nails. Some 
participants have both grey and distal banded nails occurring together but the most prominent 
nail color identified was chosen (Fig.9). Clinicians could not agree on what constituted DCO 
thus making it difficult to identify and subsequently excluded from the study. Those with normal 
nail colors were more in the study. Distal banded and grey nails affected all the fingernails and 
distal banded nails was the commonest of the nail discolorations and the easiest to identify. It can 
easily be identified in a bright (indoor) light. Figures 5 to 9 shows the study participants nail 
distribution, the percentages of nail distribution and types of nail colors. 
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 Figure 5: Distribution of nail colors giving the prevalence of distal banded and grey nails 
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 Figure 6: Normal nail colors 
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Figure 7: Distal banded or half and half nail colors 
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Figure 8: Grey nails 
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Figure 9. Grey nails with distal bands 
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4.3. Immune status of subjects 
 The relationship between nail colors and CD4 count was also explored. These 
relationships was analysed separately among those with a CD4 cell count of less than 
200cells/mm3 and those with a CD4 cell count of less than 350cells/mm3. There was a 
relationship between the CD4 count and the nail colors (P<0.0001). Table 4.7 shows the immune 
status of subjects. Immune status of subject by gender and age group is shown in table 4.8 and 
4.9. 
 
 
 
 
 
4.4: Relationship between nail colors and immune status of subjects 
 Participants within the age groups 15-44 years presented more to the clinic with a CD4 
count of ≤200 (p<0.0001) and 350 cells/mm3 (p<0.0003) with those >45 having the least 
presentation (Table 4.9). 
 Two hundred and thirty two (232) (58.8%) had their CD4 count less than 
200cells/mm3.Those with distal banded nails had the highest number of ND seen. Grey nails 
were the least recorded nail discoloration seen when compared with the participants CD4 count. 
Table 4.10-4.12 shows the relationship between these nail colors and the participants immune 
status. 
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Table 4.7: Immune status of subjects 
 
 
 
 
 
 
 
 
Table 4.8: Immune status of subjects by gender 
Immune status  Male (n=137) Female (n=257) 
≤200cells/mm3 90 (65.7%) 142 (55.3%) 
≥200cells/mm3 47 (34.3%) 115 (44.7%) 
≤350cells/mm3 113 (82.5%) 192 (74.7%) 
≥350cells/mm3 24 (17.5%) 65 (25.3%) 
 
 
Characteristics N (%)                    P-value           R.R (CI) 
≤200cells/mm3 
≥200cells/mm3 
232 (58.9)            <0.0001           2.6 (1.8-3.6) 
162 (41.1) 
 
 
305 (77.4)               0.002               1.9 (1.3-3.0)            
89 (394) 
 
  
175 (89-317)                 
≤350cells/mm3 
≥350cells/mm3  
Median CD4(IQR) 
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Table 4.9: Immune status of subjects by age group  
Age group 
15-44 
>45 
Age group  
≤200cells/mm3
194 (57%) 
38 (64.4%) 
≤200cells/mm3
P=value 
0.0001 
0.3 
≥200cells/mm3
≤350cells/mm3 
307 (77.9%) 
48 (15.6%) 
≤350cells/mm3 
P=value 
0.0003 
0.2 
≥350cells/mm3 
15-24 
25-34 
35-44 
45-54 
55-64 
65-74 
21 (39%) 
113 (61%) 
60 (61.9%) 
29 (65.9%) 
8 (66.7%) 
1 (33.3%) 
32 (60.4%) 
72 (38.9%) 
37 (38.1%) 
15 (34.1%) 
4 (33.3%) 
2 (66.7%) 
34 (64.2%) 
147 (79.5%) 
76 (78.4%) 
36 (81.8%) 
10 (83.3%) 
2 (66.7%) 
19 (35.8%) 
38 (20.5%) 
21 (21.6%) 
8 (18.2%) 
2 (16.7%) 
1 (33.3%) 
 
 
Table 4.10: Relationship between nail colors and gender 
Sex  Male (n=137) Female (n=257) 
Normal nail colors  
Distal banded nails  
Grey nails  
75 (54.7%) 
26 (19%) 
36 (26.3%) 
170 (66.1%) 
55 (21.4%) 
32 (26.3%) 
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Table 4.11: Nail color by immune status 
 
Participants  
 
No. of participants 
Nail discoloration 
Without nail discoloration 
Normal nail colors 
Distal banded nails 
Grey nails 
Participants level of CD4 counts (Immune status) 
≤200cells/mm3          201-350cells/mm3          ≥350cells/mm3 
232 (58.8%)                 89 (22.6%)                          73 (18.5%) 
117 (50.4%)                  13 (17.8%)                          19 (21.3%) 
115 (49.9%)                  60 (82.2%)                          70 (78.7%) 
115 (46.9%)                  60 (24.5%)                          70 (28.6%) 
62 (76.5%)                    4 (4.9%)                               15 (18.5%) 
55 (80.9%)                    9 (13.2%)                              4 (5.9%) 
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Table 4.12: Nail colors by age group 
 
   
Age group 
Participants nail distributions 
Normal nail               Distal banded                      Grey nails 
15-24 
25-34 
35-44 
45-54 
55-64 
65-74 
37 (15.1%)                  10 (12.3%)                    6 (8.8%) 
109 (44.5%)                42 (51.9%)                    34 (50%) 
59 (24.1%)                  18 (22.2%)                    20 (29.4%) 
29 (11.8%)                  9 (11.1%)                      6 (8.8%) 
9 (3.7%)                      1 (1.2%)                        2 (2.9%) 
2 (0.8%)                      1 (1.2%)                        0 (0.0%) 
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4.5. Significant testing and screening tool evaluation 
 The sample size of 394 was further subjected to a significant testing and to evaluate the 
strength of association between ND and CD4 count levels. Using a 2x2 table shows that there 
was a significant association (p>0.0001). The strength of this association was evaluated using the 
relative risk and the confidence intervals. Significant testing of participants with CD4 cell counts 
of ≤200cells/mm3 and ≤350cells/mm3 were analysed separately (Table 4.13 and 4.14). CD4 
≤350cells/mm3 was added because of the new ART guidelines released by WHO which Nigeria 
will soon adopt.  
4.6. Strength of association between CD4 ≤200c/mm3 and CD4 ≤350 cmm3 
 Nail discoloration was found to be associated with both CD4 counts of ≤200 and 350 
cells/mm3 (p<0.00001 & 0.002). But the strength of association increases with CD4 counts of ≤ 
200cells/mm3 (R.R; 2.3(1.8-3.6) as shown by the increasing number of participants 117(50.4%) 
with ND with CD4≤200cells/mm3 (Table 4.13). There is a better specificity and positive 
predictive values with a CD4 cell count of less than 200cells/mm3. The positive predictive 
values, specificity and strength of association between ND and CD4 count decreases with CD4 
cell count greater than 200cells/mm3 as seen in this study. Looking at the overall test in the 2 x 2 
table, accuracy (63%) was better among those participants with CD4 count ≤200cells/mm3, than 
those participants who had their CD4 count ≤ 350cells/mm3 with an accuracy result of 51%.Out 
of the total 130 (68.2%) with ND, 117(50.4%) had CD4 ≤200cells/mm3 with 13(17.8%) 
participants had their CD4 count fell between 201 to 350c/mm3. Those with CD4 count ≤ 
350cell/mm3 had a poor specificity and low PPV when compared with those with ≤200cell/mm3. 
The sensitivity is higher among those with a CD4 count ≤350cells/mm3 (87%) (Table 4.14), 
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which could have been due to more number of participants 13 (17.8%) for those populations with 
CD4 ≤350cells/mm3. Participants with CD4 count ≤200cells/mm3 and ND has a better, strength 
of association (p<00001), specificity (55%) and PPV (50%) than participants with CD4 
≤350cells/mm3.While the NPV for participants with ≤200 and 350 cells/mm3 were not really 
different (80% and 79%). 
 Since CD4 count ≤200 cells/mm3 has a better strength of association, with good 
sensitivity and specificity, good PPV and NPV and a better accuracy, it will be used for the 
discussion and conclusion part of the data analysis. 
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Table 4.13: Significance testing and screening test evaluation of association between ND and 
CD4 count ≤200 cells/mm3 
 Positive (+) 
CD4 ≤200cells/mm3 
Negative (-) 
CD4 ≥200cells/mm3 
 
Positive (+) 117 115 232 
Negative (-) 32 130 162 
Total 149 245 394 
 
 Sensitivity = 78% 
 Specificity = 55% 
 Positive predictive value = 50% 
 Negative predictive value = 80% 
 Relative Risk (Confidence Interval, CI)= 2.3 (1.8-3.6) 
 Prevalence = 38% 
 Accuracy =  63% 
 P=value= 0.00001  
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Table 4.14: Significance testing and screening test evaluation of association between nail 
discoloration and CD4 count ≤350 cells/mm3 
 Positive (+) 
CD4 ≤350 cells/mm3 
Negative (-) 
CD4 ≥350 cells/mm3 
 
Positive test n(+) 130 175 305 
Negative test (-) 19 70 89 
Total 149 245 394 
 
 Sensitivity= 87% 
 Specificity= 29% 
 Positive predictive value= 43% 
 Negative predictive value= 80% 
 Relative Risk (Confidence Interval, CI) = 1.99(1.3-3.0) 
 Prevalence = 38% 
 Accuracy = 51% 
 P-value =0.003 
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CHAPTER 5 
 DISCUSSION AND STUDY LIMITATIONS 
5.1. Discussion 
 This study has provided insight on the association of nail discoloration in HIV patients 
with CD4 count of ≤200 cells/mm3. All study participants were 17 years of age and above. The 
394 study participants had their nails compared with their levels of CD4 count for association.  
The results has shown that low CD4 count of ≤200 cells/mm3 is a risk factor for ND and has a 
significant association with distal banded and grey nails which could enhance the management of 
patients found to be HIV positive (p<0.0001; R.R:2.3[1.8-3.6]). The prevalence of ND is 38% 
and an accuracy of 63%. This deduction was made with a study sample of 394 participants with 
most of them within the age range of 15-44 years which is the age group commonly affected by 
HIV/AIDS (FMOH, 2005) in Nigeria. This age group of 15-44, had 194 (57.9%) presented with 
nail colors with a CD4 count of ≤ 200cells/mm3 which is significant (p<0.0001). Females 
(n=257; 65.2%) made up of the majority of the study sample reflecting the unequal sex 
composition of the adult ART clinic as against their male counterpart who were made up of 137 
(34.8%) of the study sample. This is in conformity with the sex distribution of patients at the 
APIN clinic (APIN clinic record) with a male to female ratio of 1:2. 
 The highest level of education attained and occupational distribution of the study was not 
different from that of APIN clinic (p>0.5). Comparing nail distribution among participants 
highest level of education and occupation shows a near even distribution of nail discolorations in 
all the participants irrespective of their level of education and occupations. These near even 
distributions now serve as a pointer to a more systemic cause with immunosuppression being the 
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most likely cause. This was so, because association was found to exist between the CD4 count 
(participants immunity) and the nail colors (p<0.0001). Relative risk was used to measure the 
strength of these relationship which indicated that the CD4 count was a risk factor for nail color 
change with a R.R of 2.6 (confidence interval: 1.8-3.6). 
 Previous reports have shown that nail discoloration associated with those who are HIV 
positive were regularly found in subjects with immunosuppression and CD4 count 
≤200cells/mm3 (Cribier et al., 1998; Scaborough et al., 2006 & Namakoola et al., 2010). An 
overall prevalence of 38% in this study is higher than the 19% reported by Levay, Botes & 
Malela, 2005 in patients attending immunology clinic at Pretoria, South Africa. It is still not clear 
whether this difference could be attributed to racial or environmental factors, especially as my 
study was carried out among patients of Fitzpatrick skin color type IV to which the black race 
belong (Derek, 1981 & Sachdeva, 2009).This may not necessary be the same for the Pretoria 
study. This prevalence would have been higher if there was uniform nail color identification 
among the clinicians. In spite of the color chart produced by Scaborough et al., (2006) which 
served as a guide, differences in color perception still occurred. Clinicians could not agree on 
what constitute DCO during the study. This area of color perception requires more skills among 
clinicians in order to identify ND as a result of immunosuppression especially with grey nails.   
A review of studies shows that distal banded nails/grey nail was strongly associated with a CD4 
count of ≤200cells/mm3 (chi-squared=0.0001) (Scaborough et al., 2006 & Namakoola et al., 
2010). With a sensitivity of 78%, a specificity of 55%, a PPV of 50% and a NPV of 80% when 
compared with other studies shows that close similarities exists between sensitivity and 
specificity with Scaborough et al., 2006 study but differed in PPV. Scaborough et al. (2006) & 
Namakoola et al., (2010) studies had a higher PPV’s of 81% and 77% compared to 50% 
 
 
 
 
 54 
 
recorded by my study. This research finding had a close similarity in NPV (80%) with 
Namakoola et al., (2010) record of 77% but differed in sensitivity and specificity. Namakoola et 
al., (2010) had a lower sensitivity of 66% and specificity of 50%. 
 In spite of the low sensitivity reported by Scaborough et al. (2006), the authors noted that 
most clinical markers of HIV progression had low sensitivity and that 75% of HIV infected 
individuals with grey/distal banded nails were denied ART using current clinical criteria. They 
therefore, recommended the use of grey/distal banded nails in resource limited setting to help 
patients to benefit from ART. This recommendation was contrasted by Namakoola et al., 2010, 
who argued that sensitivity results were rather too low for this method to be recommended as a 
tool to guide for ART initiation. This was so because a large individual group eligible for ART 
will be missed. 
 The current study, calculated values specificity of 55%, sensitivity of 78% and a PPV of 
50% tend to agree with Scaborough et al. (2006). One hundred and seventeen (or 50.4%) 
participants with distal banded nails and grey nails had a low CD4 count ≤200cells/mm3, so were 
eligible for ART. This eligibility suggests that distal banded and grey nails could assist in 
identifying those who may be in need of ART. Differences between sensitivity results obtained 
in this study and that of Scaborough et al., (2006) and Namakoola et al., (2010) raise an 
unanswered question around causation and association in respect of ND and CD4 count. If CD4 
count ≤200 cells/mm3 has an association with ND, is it likely that CD4 ≤200 cells/mm3 can 
cause ND? The answer to this question can help to resolve these differences encountered by 
Scaborough et al. (2006) and Namakoola et al., 2010 studies. Prospective epidemiological 
studies will be required to clarify this question. 
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5.2. Study Limitations 
1. The cross-sectional study design was not able to establish if low CD4 count of 
≤200cells/mm3 was a cause of ND.    
2. The consultant dermatologist left the APIN programme at the middle of data collection, 
leaving clinicians with difficulty in arriving at a consensus about ND and what 
constituted DCO and its identification. These led to fewer questionnaires being analyzed 
as most were invalid. 
3. Misclassification bias especially for grey nails which was sometimes regarded to as blue 
nails leading to exclusion.  
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CHAPTER 6 
 CONCLUSION AND RECOMMENDATIONS 
6.1. Conclusions 
 This mini-thesis reports on a survey on ND and its association with CD4 count among 
untreated HIV patients at APIN centre, JUTH. The mini-thesis was not only concerned with 
estimating the prevalence of ND in a sample of untreated patients and determining the 
association of ND and immunosuppression among the patients, but also aimed to characterise the 
types of ND seen, and further determine the sensitivity, specificity and predictive values to see if 
it could be effective in initiating ART in group of persons likely to benefit from ART.  
 This research had shown that ND had a prevalence of 38% among treatment naïve 
patients attending APIN Centre Clinic and that an association exited between CD4 count of 
≤200cells/mm3, with an accuracy of 63%. The study had further shown that CD4 count of ≤ 
200cells/mm3 was a risk factor for developing ND. Distal banded and grey nails were the 
commonest ND found. With a very strong significant association (p=0.0001) and a sensitivity of 
78%, ND can be a useful clinical indicator of early immune dysfunction mediated by HIV among 
patients in WHO stage I or II. The specificity and sensitivity of ND compared favourably with 
other WHO stage III diagnosis (Terk’s et al., 2005 & Scarborough et al., 2006). Sensitivity, PPV 
and Specificity though not too sufficiently high for a sound screening test was better than having 
a random guess. This research was meant to complement the CD4 count used as a diagnostic 
criterion for the commencement of ARV’s. 
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 Out of the 394 (100%) of the HIV infected individuals, 232 (58.8%) had CD4 ≤200 
cells/mm3 and 117(50.4%) had ND and were, qualified for ARV using the current clinical 
criteria. ND could either be a clinical sign or a symptom in HIV patients with a CD4 of ≤ 
200cell/mm3 as seen in this study. In view of this significant association between ND and low 
CD4 count; the following recommendations could be useful: 
6.2. Recommendations 
6.2.1. Recommendation 1 
That the screening for ND should complement CD4 count as an additional staging sign to help 
identify patients likely to benefit from ART especially in resource limited settings and  ND can 
be used as a screening tool to evaluate the immune status of HIV infected population in HIV care 
and treatment programmes considering the prevalence level of 30%. 
6.2.2. Recommendation 2 
That all patients with ND should be placed on co-trimoxaxole prophylaxis in line with WHO 
/national guideline recommendation on the use of co-trimoxaxole for all HIV positive patients 
with a CD4 cell count of ≤350cells/mm3 (PEPFAR, 2009). This is so because out of the 149 
participants that presented with ND, 130 (87.2%) presented with ND and CD4 count of 
≤350cells/mm3 (p<0.0003) with the remaining 19 (12.8%) participants with ND having CD4 
≥350cells/mm3. 
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6.2.3. Recommendation 3 
There should be a massive community awareness campaign to educate the public on the need to 
go for a VHCT whenever they notice any recent change in nail colors as it could be a sign of 
HIV infection with severe immunosuppression. 
6.2.4. Recommendation 4 
Clinicians and other health care workers should be trained on how to identify and to watch out 
for nail color changes in a HIV positive patients so that they can benefit from early ART in view 
of the high prevalence. Those working in health care centres should be encouraged to always 
examine all patients’ nails in order to identify those who may not be aware of their status but 
may have asymptomatic HIV with severe immunosuppression. This is important especially at the 
Primary Health Care level. 
6.2.5. Recommendation 5 
Further research is required to see if distal banded, grey nails can be a more diagnostic tool other 
than a screening tool for it to have a maximum utilisation in resource-poor settings without a 
CD4 cell count testing machine. 
6.2.6. Recommendation 6 
Since association exists between CD4 count of ≤ 200cells/mm3 and ND, further studies is 
required to determine if CD4 count of ≤200cell/mm3 is causation for ND. 
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APPENDIX 1: Participant information sheet 
 
 
 
 
UNIVERSITY OF THE WESTERN CAPE 
School of Public Health 
 
Private Bag X17 ● BELLVILLE ● 7535 ● South Africa 
Tel: 021- 959 2809, Fax: 021- 959 2872 
 
PARTICIPANT INFORMATION SHEET 
I am Ekeh Peter Nnamdi, a student studying for the Master’s in Public Health at the University 
of the Western Cape, South Africa. I am gathering information from adult above the age 15 
years. I am trying to find out the use of Nail Discolouration as a Screening Tool for Predicting 
low CD4 count in a Resource Limited Setting.The study will be used for obtaining a degree. I 
would like to ask you some questions which will take about 10-20 minutes of your time. You 
may choose not to participate in this study and your refusal will not affect you in any way. 
Whatever information you give me will not affect the care you receive from the clinic, and will 
not be given to anyone else except for improving the ART programme. The information 
collected will help us improve the utilization of ART services in this district. 
      Do I have your permission to continue with my questions?         1=yes 2=no 
Signature:             Date:                 
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Researcher’s name: EKEH PETER NNAMDI 
Address: APIN CENTRE JUTH, JOS, PLATEAU STATE, NIGERIA            
Telephone: +2348025056425            
E-mail: petekiae@yahoo.com  
Should you have any questions regarding this study or wish to report any problems you have 
experienced related to the study, please contact the study coordinator: 
Study Coordinator’s Name: Dr Ehimario Igumbor 
University of the Western Cape 
Private Bag X17, Belville 7535 
Telephone: (021)959-3520 
Cell: 082 920 0613 
Fax: (021)959-+27 21 959 2872 
Email: eigumbor@uwc.ac.za 
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APPENDIX 2: Consent form 
                    RECORD OF AN INFORMED CONSENT TO CONDUCT AN INTERVIEW 
Date:  15/05/09 
Interviewer’s name: Ekeh Peter Nnamdi 
Tel: +2348027056425 or +2347035395941 
UWC Student no: 2831634 
E-mail: petekiae@yahoo.com 
Institution: University of the Western Cape 
Interviewees’ pseudonym:  
Place at which the interview was conducted: Harvard PEPFAR APIN HIV/AIDS Clinic (APIN 
Centre), Jos University Teaching Hospital, Jos, Nigeria. 
Thank you for agreeing to allow me interview you. What follows is an explanation of the 
purpose and process of this interview. You are advised to give your consent for me to conduct an 
in-depth interview with you and to use this data for an assignment for my studies at the School of 
Public Health, UWC. 
1. Information about the interviewer 
I am Ekeh Peter, a student at the SOPH, University of the Western Cape. As part of my Masters 
in Public, I am required to carry out a research. I will be focusing on finding out the use of Nail 
Discolouration as a Screening Tool for Predicting low CD4 count in a Resource Limited Setting. 
I am accountable to Dr Ehimario Igumbor who is contactable at 021 959 3520/Cell: 082 920 
0613 or c/o SOPH Fax: 021 959 2872 or by e-mail at eigumbor@uwc.ac.za 
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Here is some information to explain the purpose and usage of my interview. 
2. The purpose and content of my interview [The purpose of my interview is to fulfil the 
part of my Masters in Public Health. The content will be questions that will centre on 
finding out the use of Nail Discolouration as a Screening Tool for Predicting low CD4 
count in a Resource Limited Setting] 
3. The interview process[getting a clearance, an interviewee, consent signing, questionnaire 
administration, physical examination and laboratory investigation] 
4. Anonymity of contributor will be guaranteed 
At all times, I will keep the source of the information confidential and refer to you or your words 
by a pseudonym or invented name which I would like you to choose. See name above. I shall 
keep any or the record of your participation locked away at all times, and destroy them after the 
data has been collected. 
5. Things that may affect your willingness to participate 
The interview may touch on issues which may affect your willingness to participate. If there is 
anything that you would prefer not to discuss, please feel free to say so. I will not be offended 
and there will be no negative consequences if you would prefer not to answer a question. I would 
appreciate your guidance should I ask anything which you see as intrusive. 
6. Agreement  
6.1 Interviewee’s agreement 
The respondent will be asked to give his consent in writing if possible 
6.2 Interviewers agreement 
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I shall keep the consents of the above research interview confidential in the sense that the 
pseudonym noted above will be used in all documents which refer to the interview. The 
contents will be used for the purposes referred to above, but may be used for published or 
unpublished research at a later stage without further consent. Any change from this 
agreement will be renegotiated with you. 
 
Signed ( Peter Nnamdi Ekeh) 
Date:  15/07/2009                                             Place: APIN CENTRE, JUTH 
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APPENDIX 3: Questionnaire 
 
Survey on nail discoloration and correlation with CD4 cell count among untreated HIV 
positive patients. 
 
Section A: 
Demographic data 
1. Patient unique ID:      
2. Year of HIV diagnosis?       
3. What is your sex?   Male=1                   Female =2   
4. What is your age (in years)?      
5. What is your occupation?  Farmer=1,    Civil servant =2, student=3,   applicant =4  , 
business=5, others=6 
6. What is your educational level?  None=1, Primary=2, Secondary =3, Post Secondary =4, 
others=5  
7. Place of residence:    Rural=1          Urban =2 
 
 
Section B: 
Clinical data 
8. Do you have any medical complaint?   Yes=1 No=2 
9. If yes, what is it?    
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10. Duration of the medical complaints: 1= less than one month, 2= one to three months, 
3=more than three months 
11. Have you been diagnosed of kidney problem in the past?     Yes=1       No=2 
12. Have you had your blood washed because of kidney problem (haemodialysis) in the past?  
Yes=1         No =2 
13. Have you been diagnosed or treated with liver problem in the past?       Yes=1     No=2     
14. Do you paint your fingernails? Yes=1           No =2 
15. Is your fingernail color changing past 7-10 years?  Yes=1        No =2Don’t know =9                
 16. Do you smoke cigarette?    Yes=1            No =2 
 17. Any past/present history of drug reaction/poisoning?  1= YES   2= NO 
18. If yes, which one?     
Examination 
19. Fingernail discoloration:  NO=1       Distal banded=2    Grey=3 Indeterminate=4   others =5 
20. General physical examination:  1=normal 2=others 
Laboratory investigations 
21. Baseline CD4 cell count:      
22. Baseline viral RNA level:      
23. HBsAg Status:       positive=1 Negative=2   
24. HCVAb Status:      positive=1Negative=2      
25. Hemoglobin level:     
26. Serum aspartate transaminase level (AST):         
Normal: men up to 38 uL, Female: up to 32 Ul 
27. Serum alanine transaminase level (ALT):      
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Normal levels: Men up to 41 Ul, Female: up to 31uL 
28. Serum alkaline phospatase (ALP):   
Normal levels: Men 40-129 u/L; Female 35-104 u/L  
29. Serum bilirubin level (total):    
Normal levels: adult up to 1.1mg/dL 
30. Serum albumin:     
Normal level: adult 3.4-4.8 g/dL 
31. Total protein:     
Normal level: adult 6.6-8.7u/l 
31. Serum Urea Level:      
Adults: 10-50 mg/dL             
32. Serum Creatinine level:   
Normal levels: Men 62-106 uMol/L; Female: 44- 80uMol/L 
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APPENDIX 4: JUTH IRB approval letter 
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APPENDIX 5: APIN clinic permission 
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APPENDIX 6: CITI Collaborative Institutional Training Initiative  
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